# For marketing purposes
Spain edition
Data as at end-February 2023
| UBS Equity Biotech (EUR) Q-acc |
| --- |
| Fund Fact Sheet |
| UBS Equity Funds > UBS Sector Funds |

| Fund description |
| --- |
| - Actively managed equity portfolio investing worldwide in biotech companies.
- Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.
- Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.
- Investment decisions are based on a disciplined investment philosophy and fundamental research.
- The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
- The exchange rate risk between USD and EUR isnot hedged.
 |

Lower risk	Higher risk
Typically lower rewards	Typically higher rewards
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| --- | --- | --- | --- | --- | --- | --- |

A category 1 rating should not be construed as indicating that the investment is free of any risk.
| Performance (basis EUR, net of fees) 1 |
| --- |
| The performance chart will be available 12 months after the fund's establishment. |

| in % | 1 year | 2 years | 3 years | Ø p.a. 2 years | Ø p.a. 3 years |
| --- | --- | --- | --- | --- | --- |
| Fund (EUR) | n.a. | n.a. | n.a. | n.a. | n.a. |
| Ref. Index 2 | n.a. | n.a. | n.a. | n.a. | n.a. |

| 1 | These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management. |
| --- | --- |
| 2 | Reference Index in currency of share class (without costs) |

The performance shown does not take account of any commissions, entry or exit charges.
| Name of fund | UBS (Lux) Equity Fund - Biotech (USD) |
| --- | --- |
| Share class | UBS (Lux) Equity Fund - Biotech (USD) (EUR) Q-acc |
| ISIN |  | LU1769088235 |
| Bloomberg |  | UBSBIOQ LX |
| Currency of fund / share class | USD/EUR |
| Launch date |  | 03.01.2023 |
| Issue/redemption |  | daily |
| Swing pricing |  | yes |
| Accounting year end |  | 30 November |
| Benchmark | MSCI US Investable Market Biotechnology 10/40 Index in EUR |
| Distribution |  | Reinvestment |
| Management fee p.a. |  | 0.82% |
| Entry charge (max.) |  | 5.00% |
| Exit charge (max.) |  | 0.00% |
| Conversion fee (max.) |  | 5.00% |
| Performance fee |  | -% |
| Ongoing charges p.a. 1 |  | 1.10% |
| Name of the Management Company | UBS Fund Management (Luxembourg) S.A., Luxembourg |
| Fund domicile |  | Luxembourg |
| Morningstar Sustainability rating 2 |  |
|  | as at 15.12.2022.The Management fee is included in the Ongoing charges. |
|  | As of 31.01.2023 |  |  |

For further information, please see the Key Investor Information Document (KIID) available at: www.ubs.com/espanafondos.
1
2

Translation (ENES, 2023-02-28):
# Con fines de marketing
## Edición España
Datos a finales de febrero 2023
| UBS Equity Biotech (EUR) Q-acc |
| --- |
| Hoja informativa del fondo |
| UBS Equity Funds > UBS Sector Funds |

| Retrato resumido del Fondo |
| --- |
| - Cartera de renta variable de gestión activa que invierte en empresas biotecnológicas de todo el mundo.
- Posibilidad eficiente para aprovechar el potencial de empresas del sector biotecnológico que trabajan en la investigación, desarrollo de productos, fabricación o en la comercialización.
- Analistas especializados en el sector biotecnológico rastrean los valores más atractivos del sector en todo el mundo.
- Las decisiones de inversión se basan en una filosofía de inversión disciplinada y análisis fundamental.
- El gestor de carteras no está supeditado al índice de referencia en lo tocante a la selección o la ponderación de las inversiones.
- El riesgo de tipo de cambio entre USD y EUR noestá cubierto.
 |

Menor riesgo	Mayor riesgo
Remuneración normalmente inferior	Remuneración normalmente superior
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| --- | --- | --- | --- | --- | --- | --- |

La categoria "1" no significa que la inversion este libre de riesgo.
| Rentabilidad (base EUR, neta de comis.) 1 |
| --- |
| El gráfico de la rentabilidad será reproducido 12 meses después del lanzamiento del Fondo. |

| en % | 1 año | 2 años | 3 años | Ø p.a. 2 años | Ø p.a. 3 años |
| --- | --- | --- | --- | --- | --- |
| Fondos (EUR) | n/d | n/d | n/d | n/d | n/d |
| índice de ref. 2 | n/d | n/d | n/d | n/d | n/d |

La rentabilidad mostrada no tiene en cuenta ninguna comisión o costes de entrada o salida.
| 1 | Estos datos son pasados. Si la divisa de denominación de un producto, servicio financiero o sus costes fuese diferente de su moneda de referencia, la rentabilidad y/o los costes podrían aumentar o disminuir como resultado de las fluctuaciones monetarias. Fuente de todos los datos y del gráfico (si no se indica otra cosa): UBS Asset Management. |
| --- | --- |
| 2 | Indice de referencia en moneda de la clase de acciones (sin costes) |

Para más información, consulte el Documento de Datos Fundamentales para el Inversor (DFI) disponible en www.ubs.com/espanafondos.